Skip to content

US · A · MEDICAL - DIAGNOSTICS & RESEARCH

Agilent Technologies, Inc. (A) intrinsic value and stock valuation

$170.38as of 2026-11-21 · Mkt cap 39.85B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Agilent Technologies, Inc. DCF and intrinsic value

InvestorsCraft values A with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from A’s statements →

Agilent Technologies, Inc. Graham Number

Graham Number: $49.68d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Santa Clara, CA 95051 agilent.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$6.95B+5.4% 5y CAGRd
20112025
Net income
$1.3B+12.6% 5y CAGRd
20112025
Free cash flow
$1.15B+7.5% 5y CAGRd
20112025
Total equity
$6.74B+6.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$6.95B$6.51B$6.83B$6.85B$6.32B
Operating income$1.48B$1.49B$1.35B$1.62B$1.35B
Net income$1.3B$1.29B$1.24B$1.25B$1.21B
EPSd$4.59M$4.43M$4.19M$4.18M$3.94M
Operating cash flow$1.56B$1.75B$1.77B$1.31B$1.49B
Capital expenditure-$-407M-$-378M-$-298M-$-291M-$-189M
Free cash flow$1.15B$1.37B$1.47B$1.02B$1.3B
Total assets$12.7B$11.8B$10.8B$10.5B$10.7B
Total debt$3.35B$3.57B$2.74B$2.77B$2.73B
Net debt$1.57B$2.25B$1.15B$1.72B$1.25B
Total equity$6.74B$5.9B$5.85B$5.31B$5.39B
Cash and short-term investments$1.79B$1.33B$1.59B$1.05B$1.58B
Income statement
20252024202320222021
Revenue$6.95B$6.51B$6.83B$6.85B$6.32B
Cost of revenue$3.31B$2.98B$3.37B$3.13B$2.91B
Gross profit$3.64B$3.54B$3.47B$3.72B$3.41B
Research and development expenses$455M$479M$481M$467M$441M
Selling, general and administrative expenses$1.71B$1.52B$1.63B$1.64B$1.62B
Other expenses$0.00$50M$0.00$0.00$0.00
Operating expenses$2.16B$2.05B$2.12B$2.1B$2.06B
Cost and expenses$5.47B$5.02B$5.48B$5.23B$4.97B
Interest income$62M$80M$51M$9M$2M
Interest expense$112M$96M$95M$84M$81M
Depreciation and amortization$288M$257M$271M$317M$321M
Ebitda$1.84B$1.87B$1.7B$1.91B$1.76B
Operating income$1.48B$1.49B$1.35B$1.62B$1.35B
Total other income/expenses, net-$-44M$33M-$-11M-$-114M$13M
Income before tax$1.44B$1.52B$1.34B$1.5B$1.36B
Income tax expense$132M$232M$99M$250M$150M
Net income$1.3B$1.29B$1.24B$1.25B$1.21B
Weighted average shares outstanding$283M$290M$294M$299M$304M
Weighted average diluted shares outstanding$284M$291M$296M$300M$307M
Balance sheet
20252024202320222021
Cash and short-term investments$1.79B$1.33B$1.59B$1.05B$1.58B
Net receivables$1.49B$1.32B$1.29B$1.41B$1.17B
Inventory$1.03B$991M$1.03B$1.04B$830M
Total current assets$4.59B$3.96B$4.19B$3.78B$3.8B
Property, plant and equipment, net$2.02B$1.96B$1.42B$1.1B$945M
Goodwill and intangible assets$4.92B$5.02B$4.44B$4.77B$4.96B
Long-term investments$133M$175M$164M$195M$185M
Total non-current assets$8.13B$7.89B$6.58B$6.75B$6.91B
Total assets$12.7B$11.8B$10.8B$10.5B$10.7B
Accounts payable$570M$540M$418M$580M$446M
Short-term debt$304M$87M$0.00$36M$0.00
Deferred revenue$624M$544M$505M$461M$441M
Total current liabilities$2.35B$1.9B$1.6B$1.86B$1.71B
Long-term debt$3.05B$3.49B$2.74B$2.73B$2.73B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.64B$4.05B$3.32B$3.37B$3.61B
Capital lease obligations$0.00$184M$0.00$0.00$0.00
Total liabilities$5.99B$5.95B$4.92B$5.23B$5.32B
Common stock$3M$3M$3M$3M$3M
Retained earnings$1.39B$750M$782M$324M$348M
Accumulated other comprehensive income (loss)-$-226M-$-305M-$-327M-$-347M-$-282M
Total equity$6.74B$5.9B$5.85B$5.31B$5.39B
Total investments$133M$175M$164M$195M$276M
Total debt$3.35B$3.57B$2.74B$2.77B$2.73B
Net debt$1.57B$2.25B$1.15B$1.72B$1.25B
Cash flow statement
20252024202320222021
Net income$434M$1.29B$1.24B$1.25B$1.21B
Depreciation and amortization$288M$257M$271M$317M$321M
Stock-based compensation$128M$129M$111M$125M$110M
Change in working capital-$-58M$83M-$-116M-$-478M-$-102M
Accounts receivable-$-149M$7M$132M-$-321M-$-128M
Inventory$45M$34M-$-33M-$-248M-$-136M
Accounts payable$16M$103M-$-171M$121M$64M
Net cash provided by operating activities$1.56B$1.75B$1.77B$1.31B$1.49B
Investments in property, plant and equipment-$-207M-$-378M-$-298M-$-291M-$-189M
Acquisitions, net$4M-$-862M-$-1M-$-52M-$-546M
Net cash used for investing activities-$-394M-$-1.26B-$-310M-$-338M-$-749M
Common stock issued$72M$0.00$0.00$0.00$0.00
Common stock repurchased-$-425M-$-1.15B-$-575M-$-1.14B-$-788M
Dividends paid-$-282M-$-274M-$-265M-$-250M-$-236M
Net cash used for financing activities-$-715M-$-752M-$-930M-$-1.37B-$-696M
Net change in cash$459M-$-261M$537M-$-434M$43M
Cash at end of period$1.79B$1.33B$1.59B$1.06B$1.49B
Operating cash flow$1.56B$1.75B$1.77B$1.31B$1.49B
Capital expenditure-$-407M-$-378M-$-298M-$-291M-$-189M
Free cash flow$1.15B$1.37B$1.47B$1.02B$1.3B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Agilent Technologies, Inc.

        Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

        CEO
        Padraig McDonnell
        Employees
        18.1K
        Beta
        1.25

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Agilent Technologies, Inc. (A)?

        Agilent Technologies, Inc. (A) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is A undervalued?

        A trades at a price of $170.38 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.